ArticleJournal of tissue engineering and regenerative medicine2019
Nanoparticulate mineralized collagen glycosaminoglycan materials directly and indirectly inhibit osteoclastogenesis and osteoclast activation.
Article in Journal of tissue engineering and regenerative medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 40 citations in OpenAlex.
- Mineralized collagen scaffold pore architecture and glycosaminoglycan content biases anti-inflammatory macrophage phenotype.bioRxiv : the preprint server for biology · 2026Article
- Assessment of Bone Regeneration in Rabbit Calvarial Defects Treated With Mineralized Collagen-Based Scaffolds Using In Vivo MicroCT and Three-Dimensional Rendering.Current protocols · 2026Article
- Relyophilized collagen scaffold to improve handling and small molecule loading.bioRxiv : the preprint server for biology · 2026Article
- Evaluating Mineral Deposition in Bone-Regenerative Collagen-Based Scaffolds Using High-Resolution microCT and 3D Computational Segmentation.Current protocols · 2026Article
- Orai1 is Required for Osteogenic Differentiation on Nanoparticulate Mineralized Collagen Glycosaminoglycan Materials.Macromolecular bioscience · 2025Article
- Strategies for Craniofacial Tissue Engineering: Innovations for Scalable Bone Regeneration.Plastic and aesthetic research · 2025Article
- Biomaterial Cues for Regulation of Osteoclast Differentiation and Function in Bone Regeneration.Advanced therapeutics · 2025Article
- Donor Sex and Passage Conditions Influence MSC Osteogenic Response in Mineralized Collagen Scaffolds.Advanced healthcare materials · 2024Article
- Correlating Material Properties to Osteoprotegerin Expression on Nanoparticulate Mineralized Collagen Glycosaminoglycan Scaffolds.Advanced healthcare materials · 2024Article
- Paracrine signals influence patterns of fibrocartilage differentiation in a lyophilized gelatin hydrogel for applications in rotator cuff repair.Biomaterials science · 2024Article
- Evaluating osteogenic effects associated with the incorporation of ascorbic acid in mineralized collagen scaffolds.Journal of biomedical materials research. Part A · 2024Article
- DONOR VARIABILITY IN HUMAN MESENCHYMAL STEM CELL OSTEOGENIC RESPONSE AS A FUNCTION OF PASSAGE CONDITIONS AND DONOR SEX.bioRxiv : the preprint server for biology · 2023Article
- Modulating Temporospatial Phosphate Equilibrium by Nanoparticulate Mineralized Collagen Materials Induces Osteogenesis via PiT-1 and PiT-2.Advanced healthcare materials · 2023Article
- The effects of seeding density and osteoclastic supplement concentration on osteoclastic differentiation and resorption.Bone reports · 2023Article
- Evaluation of bacterial attachment on mineralized collagen scaffolds and addition of manuka honey to increase mesenchymal stem cell osteogenesis.Biomaterials · 2023Article
- Osteoprotegerin-eluting nanoparticulate mineralized collagen scaffolds improve skull regeneration.Biomaterials advances · 2023Article
- Amnion and chorion matrix maintain hMSC osteogenic response and enhance immunomodulatory and angiogenic potential in a mineralized collagen scaffold.Frontiers in bioengineering and biotechnology · 2022Article
- β-Catenin Limits Osteogenesis on Regenerative Materials in a Stiffness-Dependent Manner.Advanced healthcare materials · 2021Article
- Repair of critical-size porcine craniofacial bone defects using a collagen-polycaprolactone composite biomaterial.Biofabrication · 2021Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
Abstract
The ability of the extracellular matrix (ECM) to direct cell fate has generated the potential for developing a materials-only strategy for tissue regeneration. Previously, we described a nanoparticulate mineralized collagen glycosaminoglycan (MC-GAG) material that efficiently induced osteogenic differentiation of human mesenchymal stem cells (hMSCs) and calvarial bone healing without exogenous growth factors or progenitor cell expansion. In this work, we evaluated the interactions between MC-GAG and primary human osteoclasts (hOCs). In the absence of hMSCs, mineralized Col-GAG materials directly inhibited hOC viability, proliferation, and resorption in contrast to nonmineralized Col-GAG, which demonstrated a modest inhibition of resorptive activity only. Cocultures containing differentiating hMSCs with hOCs demonstrated increased hOC-mediated resorption only on Col-GAG while MC-GAG cocultures continued to inhibit resorption. Unlike Col-GAG, hMSCs on MC-GAG expressed increased amounts of osteoprotegerin (OPG) protein, the major endogenous osteoclast inhibitor. Interestingly, OPG expression was found to be antagonized by small mothers against decapentaplegic1/5 (Smad1/5) phosphorylation, an obligate pathway for osteogenic differentiation of hMSCs on MC-GAG, and potentiated by extracellular signal-regulated kinase (ERK1/2) phosphorylation. Collectively, these results suggested that the MC-GAG material both directly inhibited the osteoclast viability, proliferation, and resorptive activity as well as induced hMSCs to secrete osteoprotegerin, an antiosteoclastogenic factor, via a signalling pathway distinct from osteogenic differentiation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.